CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Recruiting

Phase 2

Mosunetuzumab & PolatuzumabCAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Sponsor:

Lazaros Lekakis

Code:

NCT05260957

Conditions

Refractory Non-Hodgkin Lymphoma

Relapsed Non Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Mosunetuzumab

Polatuzumab

CAR-T Cell Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Lazaros Lekakis on 2024-12-19.